This commentary concerns the paper 'Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation' by Grigg et al 1 in this issue of Leukemia 2003.
TO THE EDITOR
This commentary concerns the paper 'Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation' by Grigg et al 1 in this issue of Leukemia 2003.
The author's experience is very similar to ours: 2 both patients showed an hematological relapse after allogeneic bone marrow transplantation (BMT) and a molecular remission with a reconstitution of a full chimera has been obtained after treatment with arsenic trioxide, as monochemotherapy in our case and in association with all-trans retinoic acid in the case reported by Grigg et al.
A number of issues are raised by these observations. Relapsed acute promyelocytic leukemia patients have a high probability of achieving a second complete remission (CR), but the maintenance of the new molecular remission attained is a critical issue. Although relatively high rates of molecular remission have been reported among patients in hematological relapse treated with arsenic trioxide, there is preliminary evidence that molecular remissions obtained are generally not long lasting. Furthermore, results of other novel therapeutic approaches such as antibodies targeting CD33 and liposomal all-trans retinoic acid are very preliminary. 3, 4 Even if the outcome information for allogeneic BMT in second CR is based only on registry data, we think that in patients with an HLAidentical sibling donor it is advisable to recommend a transplant procedure as the 6-year estimated relapse rate after this procedure is only about 15% (Sanz MA et al. Blood 2000; 96: 522a; abstract). In view of the relatively large number of treatment options available for treating molecular relapse, RT-PCR for minimal residual disease monitoring should be routinely performed post-transplant.
Arsenic trioxide in our patient as well as in the case reported by Grigg et al showed a promising activity not only in inducing the disappearance of the leukemic clone, but also in inducing the restoration of a full chimera. This allowed sustained long-lasting molecular remission even if both patients were in overt hematological relapses. On the basis of our observation, we agree with the approach proposed by Grigg et al to treat with arsenic trioxide those cases showing a molecular relapse or a persistence of PML-RARa transcript after allogeneic transplant.
A Tedeschi M Montillo E Morra
Division of Hematology, Niguarda Ca' Granda Hospital Milano, Italy
